Equities

AlzeCure Pharma AB

AlzeCure Pharma AB

Actions
  • Price (SEK)1.96
  • Today's Change-0.035 / -1.76%
  • Shares traded32.63k
  • 1 Year change-57.52%
  • Beta0.4305
Data delayed at least 15 minutes, as of Jul 26 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimer’s disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (Aβ) protein in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-37.43m
  • Incorporated2016
  • Employees11.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NextCell Pharma AB12.45m-39.37m109.64m----1.17--8.81-0.9046-0.90460.2861.280.140614.067.20---44.45-34.92-50.09-37.0612.04-68.21-316.25-538.604.36--0.00--80.9672.85-15.21------
Spago Nanomedical AB (publ)1.47m-35.58m116.30m12.00--2.19--79.33-0.3129-0.31290.01130.15250.0324--9.91112,769.20-78.60-20.19-93.27-20.97-5.25---2,426.88-4,853.45----0.00--14.14---7.72------
AroCell AB (publ)44.79m-56.13m124.40m----0.8123--2.78-0.2437-0.24370.19440.66480.23255.825.63---29.14-29.25-31.00-31.371.88-9.85-125.33-231.195.16--0.00--16.37122.92-0.5494------
Coegin Pharma AB0.00-27.98m140.37m0.00--10.78-----2.65-2.650.000.64030.00-------125.24-122.02-201.53-154.70-------28,466.75---170.650.00------20.60------
Biosergen AB0.00-28.90m149.88m4.00--2.16-----0.3579-0.35790.000.24970.00----0.00-113.63---147.91--------------0.00------32.25------
Ascelia Pharma AB0.00-88.76m156.80m13.00--2.58-----2.63-2.630.001.800.00----0.00-65.17---78.39--------------0.2302------16.72------
Xintela AB377.00k-49.24m166.08m--------440.53-0.1217-0.12170.0008-0.01360.0193--0.0447---252.59-181.06---391.61100.00---13,061.54-235,894.00---49.47-------45.5418.32---61.47--
AlzeCure Pharma AB0.00-37.43m168.32m11.00--9.21-----0.5685-0.56850.000.21220.00----0.00-92.80-52.78-115.25-57.01------------0.00------33.91------
Prolight Diagnostics AB (publ)0.00-136.81m170.82m16.00--1.15-----0.3953-0.39530.000.24880.00----0.00-64.42---84.94--------------0.00-----------13.84--
Active Biotech AB publ0.00-44.80m177.98m8.00--8.85-----0.1651-0.16510.000.05560.00-------122.57-57.97-179.56-97.83-------1,454.61----0.1145------21.54------
SenzaGen AB-100.00bn-100.00bn206.53m32.00--2.58----------2.71-----------25.84---29.85--68.62---132.291.24--0.0368--19.3990.3211.30---21.10--
Kancera AB0.00-60.35m208.68m5.00--2.22-----0.7267-0.72670.000.77490.00----0.00-52.92-54.82-65.84-66.21--96.28---7,249.06----0.00-------23.64------
Alzinova AB300.00k-17.17m210.06m5.00--1.28--700.20-0.3221-0.32210.00561.980.0027--0.445960,000.00-15.32-10.77-16.22-11.276,018.45---5,723.82-18,447.90----0.0073-------25.92--15.81--
Biovica International AB7.29m-124.82m218.96m32.00--2.45--30.03-2.12-2.120.12181.150.0480.23226.50227,843.80-82.20-51.94-99.16-58.1894.34181.68-1,712.00-2,217.413.04--0.0749--115.4919.39-12.97---54.31--
Exact Therapeutics AS0.00-47.41m224.98m8.00--5.09-----1.51-1.510.001.410.00-------67.21-40.21-86.14-45.67-----------16,578.570.0258-------20.52------
Data as of Jul 26 2024. Currency figures normalised to AlzeCure Pharma AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.